Clinical Trials
14 trialsNCT02399371 2026-05-08
Pembrolizumab in Treating Patients With Malignant Mesothelioma
University of Chicago
Phase 2 Completed
NCT01196936 2026-01-05
LDTam
University of Alabama at Birmingham
Phase 2 Active not recruiting
NCT03370718 2024-12-10
Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00611351 2023-10-23
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
University of Nebraska
Phase 2 Completed
NCT00665457 2023-09-13
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
University of Nebraska
Phase 2 Terminated
NCT01267812 2023-07-27
Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
City of Hope Medical Center
Phase 2 Completed
NCT02542397 2022-11-03
LCI-NOS-PAIN-001: A Prospective, Pharmacogenomic-Driven Study of Pain Management in Oncology Outpatients
Wake Forest University Health Sciences
Phase 2 Terminated
NCT00936832 2022-08-30
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
Federation Francophone de Cancerologie Digestive
Phase 2 Withdrawn
NCT03216499 2022-05-09
PT2385
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01192815 2020-05-12
Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT01557959 2018-06-29
Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT00764322 2017-08-01
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01205711 2014-07-08
FOLFERA
Cardiff University
Phase 2 Completed
NCT00645866 2011-05-16
Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer
Mayo Clinic
Phase 2 Completed